LRRK2-targeting antisense oligonucleotide in Parkinson’s disease: a phase 1 randomized controlled trial

Nature Medicine 2026

View at publisher
Authors: Omar S. Mabrouk, B. Tichler, H. Moore Arnold, Eva C. Thoma, Sara M. Alexanian, Jingxian Chen, Tzu-Ying Liu, Beth Hirschhorn, Rodrigo Llorens‐Arenas, John W. Annand, Unnati Kapadnis, Alan A Shomo
+24 more Kelly E. Glajch, Kyle Ferber, Yuka Moroishi, Julie Czerkowicz, Jennifer Inra, Ronald B. Postuma, Tanya Gurevich, Pablo Mir, Huw R. Morris, Jason Aldred, Matthew Brodsky, Aaron Ellenbogen, Danielle Larson, Christopher M. Tolleson, Andrew Siderowf, Charalampos Tzoulis, Ernest Balaguer, Maria J. Martí, Hien Zhao, Holly Kordasiewicz, Roger Lane, Warren D. Hirst, Stephanie Fradette, Danielle Graham
DOI: 10.1038/s41591-026-04262-4
Cited by: 2
References: 62

Fields of Study & Subjects

Parkinson's Disease Mechanisms and Treatments Parkinson's Disease and Spinal Disorders Neurological disorders and treatments

Publication details

Journal / source
Nature Medicine
Publisher
Springer Science and Business Media LLC
Volume
32
Issue
4
Pages
1421–1431
Publication date
24 March 2026
Language
EN